{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T15:16:51Z","timestamp":1784215011221,"version":"3.55.0"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T00:00:00Z","timestamp":1543449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European and Developing Countries Clinical Trials Partnership (NL)","award":["IP.2007.33112.001"],"award-info":[{"award-number":["IP.2007.33112.001"]}]},{"name":"German Ministry of Education and Research","award":["01KA1202"],"award-info":[{"award-number":["01KA1202"]}]},{"DOI":"10.13039\/100004441","name":"Swedish International Development Cooperation Agency","doi-asserted-by":"crossref","award":["75000516"],"award-info":[{"award-number":["75000516"]}],"id":[{"id":"10.13039\/100004441","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0206838","type":"journal-article","created":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T18:42:05Z","timestamp":1543516925000},"page":"e0206838","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":28,"title":["Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140\/GLA vaccines in a phase II randomized factorial trial design"],"prefix":"10.1371","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4691-9920","authenticated-orcid":true,"given":"Edna O.","family":"Viegas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arne","family":"Kroidl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia J.","family":"Munseri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Missanga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotta","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelson","family":"Tembe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asli","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agricola","family":"Joachim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Mann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christof","family":"Geldmacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Fleck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"St\u00f6hr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Scarlatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Aboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Bakari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Maboko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hoelscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"Wahren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merlin L.","family":"Robb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5696-0340","authenticated-orcid":true,"given":"Jonathan","family":"Weber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheena","family":"McCormack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnel","family":"Biberfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilesh V.","family":"Jani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Sandstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eligius","family":"Lyamuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"TaMoVac study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2018,11,29]]},"reference":[{"key":"ref1","unstructured":"UNAIDS JUN-PoHA. AIDS by the numbers Geneva, Switzerland: 2017."},{"issue":"6","key":"ref2","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2174\/1570162X113116660051","article-title":"Lessons learned from HIV vaccine clinical efficacy trials","volume":"11","author":"TA Day","year":"2013","journal-title":"Curr HIV Res"},{"issue":"12","key":"ref3","doi-asserted-by":"crossref","first-page":"a007351","DOI":"10.1101\/cshperspect.a007351","article-title":"Human immunodeficiency virus vaccine trials","volume":"2","author":"RJ O'Connell","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"23","key":"ref4","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand","volume":"361","author":"S Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"issue":"14","key":"ref5","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1056\/NEJMoa1113425","article-title":"Immune-correlates analysis of an HIV-1 vaccine efficacy trial","volume":"366","author":"BF Haynes","year":"2012","journal-title":"N Engl J Med"},{"issue":"8","key":"ref6","doi-asserted-by":"crossref","first-page":"e21225","DOI":"10.1371\/journal.pone.0021225","article-title":"A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204)","volume":"6","author":"GJ Churchyard","year":"2011","journal-title":"PLoS One"},{"issue":"5","key":"ref7","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/COH.0b013e3283632c26","article-title":"Novel directions in HIV-1 vaccines revealed from clinical trials","volume":"8","author":"JL Excler","year":"2013","journal-title":"Curr Opin HIV AIDS"},{"issue":"5","key":"ref8","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/infdis\/jiq105","article-title":"Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles","volume":"203","author":"PA Goepfert","year":"2011","journal-title":"J Infect Dis"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.20071331","article-title":"An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses","volume":"205","author":"A Harari","year":"2008","journal-title":"J Exp Med"},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"e55831","DOI":"10.1371\/journal.pone.0055831","article-title":"Safety and immunogenicity of DNA and MVA HIV-1 subtype C vaccine prime-boost regimens: a phase I randomised Trial in HIV-uninfected Indian volunteers","volume":"8","author":"S Mehendale","year":"2013","journal-title":"PLoS One"},{"issue":"46","key":"ref11","doi-asserted-by":"crossref","first-page":"8417","DOI":"10.1016\/j.vaccine.2011.08.001","article-title":"Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania","volume":"29","author":"M Bakari","year":"2011","journal-title":"Vaccine"},{"issue":"4","key":"ref12","doi-asserted-by":"crossref","first-page":"e0119629","DOI":"10.1371\/journal.pone.0119629","article-title":"Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial","volume":"10","author":"PJ Munseri","year":"2015","journal-title":"PLoS One"},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","first-page":"e0131748","DOI":"10.1371\/journal.pone.0131748","article-title":"HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA\/MVA Vaccinees: A Phase I Randomized Trial","volume":"10","author":"C Nilsson","year":"2015","journal-title":"PLoS One"},{"key":"ref14","article-title":"Intradermal HIV-1 DNA Immunization Using Needle-Free Zetajet Injection Followed by HIV-Modified Vaccinia Virus Ankara Vaccination Is Safe and Immunogenic in Mozambican Young Adults: A Phase I Randomized Controlled Trial","author":"EO Viegas","year":"2017","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"4","key":"ref15","doi-asserted-by":"crossref","first-page":"e0118486","DOI":"10.1371\/journal.pone.0118486","article-title":"Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults","volume":"10","author":"A Joachim","year":"2015","journal-title":"PLoS One"},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1086\/592507","article-title":"Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara","volume":"198","author":"E Sandstrom","year":"2008","journal-title":"J Infect Dis"},{"issue":"8","key":"ref17","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1089\/aid.2016.0251","article-title":"Three-Year Durability of Immune Responses Induced by HIV-DNA and HIV-Modified Vaccinia Virus Ankara and Effect of a Late HIV-Modified Vaccinia Virus Ankara Boost in Tanzanian Volunteers","volume":"33","author":"A Joachim","year":"2017","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"3","key":"ref18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1089\/aid.2013.0149","article-title":"Broad and potent cellular and humoral immune responses after a second late HIV-modified vaccinia virus ankara vaccination in HIV-DNA-primed and HIV-modified vaccinia virus Ankara-boosted Swedish vaccinees","volume":"30","author":"C Nilsson","year":"2014","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"3","key":"ref19","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.vaccine.2007.10.041","article-title":"Intradermal\/subcutaneous immunization by electroporation improves plasmid vaccine delivery and potency in pigs and rhesus macaques","volume":"26","author":"LA Hirao","year":"2008","journal-title":"Vaccine"},{"issue":"10","key":"ref20","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.4161\/hv.25473","article-title":"Comparison of intradermal and intramuscular delivery followed by in vivo electroporation of SIV Env DNA in macaques","volume":"9","author":"V Kulkarni","year":"2013","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"ref21","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1093\/infdis\/jit236","article-title":"Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery","volume":"208","author":"SA Kalams","year":"2013","journal-title":"J Infect Dis"},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"e19252","DOI":"10.1371\/journal.pone.0019252","article-title":"In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers","volume":"6","author":"S Vasan","year":"2011","journal-title":"PLoS One"},{"key":"ref23","article-title":"Advances in Molecular Retrovirology","author":"A. Bolhassani","year":"2016"},{"issue":"12","key":"ref24","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1086\/508748","article-title":"Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand","volume":"194","author":"P Pitisuttithum","year":"2006","journal-title":"J Infect Dis"},{"issue":"5","key":"ref25","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1086\/428404","article-title":"Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection","volume":"191","author":"NM Flynn","year":"2005","journal-title":"J Infect Dis"},{"issue":"5","key":"ref26","doi-asserted-by":"crossref","first-page":"e0155702","DOI":"10.1371\/journal.pone.0155702","article-title":"Boosting with Subtype C CN54rgp140 Protein Adjuvanted with Glucopyranosyl Lipid Adjuvant after Priming with HIV-DNA and HIV-MVA Is Safe and Enhances Immune Responses: A Phase I Trial","volume":"11","author":"A Joachim","year":"2016","journal-title":"PLoS One"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrsc.2017.03.001","article-title":"High prevalence of ST-elevation, early repolarization, and left ventricular hypertrophy during the eligibility assessment for an HIV vaccine trial in young, healthy Tanzanians","volume":"26","author":"MP Mann P","year":"2017","journal-title":"Clinical Trials and Regulatory Science in Cardiology"},{"issue":"6","key":"ref28","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.ymthe.2005.06.473","article-title":"Multigene\/multisubtype HIV-1 vaccine induces potent cellular and humoral immune responses by needle-free intradermal delivery","volume":"12","author":"A Brave","year":"2005","journal-title":"Mol Ther"},{"issue":"42","key":"ref29","doi-asserted-by":"crossref","first-page":"5885","DOI":"10.1016\/j.vaccine.2009.07.039","article-title":"Design and evaluation of multi-gene, multi-clade HIV-1 MVA vaccines","volume":"27","author":"PL Earl","year":"2009","journal-title":"Vaccine"},{"issue":"23","key":"ref30","doi-asserted-by":"crossref","first-page":"11367","DOI":"10.1128\/JVI.74.23.11367-11376.2000","article-title":"Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C\/B') recombinant strain in China","volume":"74","author":"L Su","year":"2000","journal-title":"J Virol"},{"issue":"2","key":"ref31","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/08892220150217247","article-title":"Near full-length clones and reference sequences for subtype C isolates of HIV type 1 from three different continents","volume":"17","author":"CM Rodenburg","year":"2001","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"ref32","doi-asserted-by":"crossref","first-page":"e88979","DOI":"10.1371\/journal.pone.0088979","article-title":"GLA-AF, an emulsion-free vaccine adjuvant for pandemic influenza","volume":"9","author":"CH Clegg","year":"2014","journal-title":"PLoS One"},{"key":"ref33","unstructured":"(DAIDS) DoA. Table for Grading The Severity of Adult and Pediatric Adverse Events. 2004 Clarification August 2009;Version 1.0."},{"issue":"5","key":"ref34","doi-asserted-by":"crossref","first-page":"e97391","DOI":"10.1371\/journal.pone.0097391","article-title":"Reference values for clinical laboratory parameters in young adults in Maputo, Mozambique","volume":"9","author":"N Tembe","year":"2014","journal-title":"PLoS One"},{"issue":"18","key":"ref35","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00730-17","article-title":"Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen","volume":"91","author":"A Bauer","year":"2017","journal-title":"J Virol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/00031305.2000.10474560","article-title":"Simple and effective confidence intervals for proportions and differences of proportions result from adding two successes and two failures","volume":"54","author":"A Agresti","year":"2000","journal-title":"The American Statistician"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3389\/fimmu.2017.00149","article-title":"A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein\/Adjuvant HIV Vaccines in Two Immunization Regimes","volume":"8","author":"S Joseph","year":"2017","journal-title":"Front Immunol"},{"issue":"12","key":"ref38","doi-asserted-by":"crossref","first-page":"e3919","DOI":"10.1371\/journal.pone.0003919","article-title":"Reference intervals in healthy adult Ugandan blood donors and their impact on conducting international vaccine trials","volume":"3","author":"LA Eller","year":"2008","journal-title":"PLoS One"},{"issue":"1","key":"ref39","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/lc.1999.v133.a94931","article-title":"Benign ethnic neutropenia: what is a normal absolute neutrophil count?","volume":"133","author":"TB Haddy","year":"1999","journal-title":"J Lab Clin Med"},{"issue":"10","key":"ref40","doi-asserted-by":"crossref","first-page":"e3327","DOI":"10.1371\/journal.pone.0003327","article-title":"Reference ranges for the clinical laboratory derived from a rural population in Kericho, Kenya","volume":"3","author":"RS Kibaya","year":"2008","journal-title":"PLoS One"},{"key":"ref41","article-title":"Safety and Immunogenicity of PENNVAX(R)-G DNA Prime Administered by Biojector(R) 2000 or CELLECTRA(R) Electroporation Device with Modified Vaccinia Ankara-CMDR Boost","author":"JA Ake","year":"2017","journal-title":"J Infect Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0206838","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T22:12:05Z","timestamp":1720822325000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0206838"}},"subtitle":[],"editor":[{"given":"Alan","family":"Landay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,11,29]]},"references-count":41,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,11,29]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0206838","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,29]]}}}